Acton, MA– Insulet Corporation, maker of the Omnipod® tubeless insulin pump, will present new data and insights at the American Diabetes Association’s 85th Scientific Sessions in Chicago, showcasing the continued benefits of its Omnipod® 5 system for people with diabetes.
The company will share expanded findings from its pivotal SECURE-T2D and RADIANT clinical trials, which explore the impact of automated insulin delivery (AID) in individuals with type 2 and type 1 diabetes, respectively. Alongside the trial data, Insulet will also present real-world outcomes from more than 23,000 people in the U.S. with type 2 diabetes using Omnipod 5.
“We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials,” said Dr. Trang Ly, Chief Medical Officer at Insulet. “We look forward to conversations with healthcare providers about what these outcomes mean and how they can help optimize therapy for patients.”
Insulet previously introduced the SECURE-T2D trial at last year’s ADA conference as the first large pivotal study of AID in type 2 diabetes. Earlier this year, the company also released results from the RADIANT study, the first randomized controlled trial examining a direct switch from multiple daily injections to AID in patients with poorly controlled type 1 diabetes.
In addition to formal presentations and panel discussions, Insulet’s ADA booth will feature interactive exhibits, including live demonstrations by clinical experts, podcasts, and a comic book experience centered on a superhero with type 1 diabetes — designed to raise awareness and engagement among younger patients.
The ADA’s annual meeting runs from June 20 to 23 at McCormick Place Convention Center in Chicago.
